US 11,773,132 B2
Cyclic di-nucleotides as stimulator of interferon genes modulators
Yuntao Song, Palo Alto, CA (US); Anrong Li, Foster City, CA (US); and Xiaoqi Chen, Palo Alto, CA (US)
Assigned to Beijing Xuanyi PharmaSciences Co., Ltd., Beijing (CN)
Appl. No. 16/643,127
Filed by Beijing Xuanyi PharmaSciences Co., Ltd., Beijing (CN)
PCT Filed Aug. 30, 2018, PCT No. PCT/IB2018/056658
§ 371(c)(1), (2) Date Feb. 28, 2020,
PCT Pub. No. WO2019/043634, PCT Pub. Date Mar. 7, 2019.
Claims priority of provisional application 62/660,565, filed on Apr. 20, 2018.
Claims priority of provisional application 62/552,148, filed on Aug. 30, 2017.
Prior Publication US 2020/0331957 A1, Oct. 22, 2020
Int. Cl. C07H 21/04 (2006.01); C07H 21/02 (2006.01)
CPC C07H 21/04 (2013.01) [C07H 21/02 (2013.01)] 15 Claims
 
1. A compound of formula (II-C), (II-D), or (II-F):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
Qa and Qb are each independently selected from:

OG Complex Work Unit Chemistry
R1 is each independently hydrogen, halogen, or —N(Rcl)2;
Rcl is each independently H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl-, 3-6 membered heterocyclyl, (3-6 membered heterocyclyl)-C1-6 alkyl-, 5-6 membered aryl, (5-6 membered aryl)-C1-6 alkyl-, 5-6 membered heteroaryl, or (5-6 membered heteroaryl)-C1-6 alkyl-; and
X2 and Y2 are each independently SH, OH, or BH3−, wherein at least one of X2 and Y2 is BH3−.